APA (7th ed.) Citation

Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., . . . Slamon, D. (2015). Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): A phase 3, randomised, double-blind, multicentre trial. The lancet oncology, 16(7), 816-829. https://doi.org/10.1016/S1470-2045(15)00051-0

Chicago Style (17th ed.) Citation

Hurvitz, Sara A., et al. "Combination of Everolimus with Trastuzumab Plus Paclitaxel as First-line Treatment for Patients with HER2-positive Advanced Breast Cancer (BOLERO-1): A Phase 3, Randomised, Double-blind, Multicentre Trial." The Lancet Oncology 16, no. 7 (2015): 816-829. https://doi.org/10.1016/S1470-2045(15)00051-0.

MLA (9th ed.) Citation

Hurvitz, Sara A., et al. "Combination of Everolimus with Trastuzumab Plus Paclitaxel as First-line Treatment for Patients with HER2-positive Advanced Breast Cancer (BOLERO-1): A Phase 3, Randomised, Double-blind, Multicentre Trial." The Lancet Oncology, vol. 16, no. 7, 2015, pp. 816-829, https://doi.org/10.1016/S1470-2045(15)00051-0.